Nu Skin (NUS) AI Stock Analysis

• Market Cap: $566.25M
• Dividend Yield: 2.1%
• Average Volume (3M): 538.52K
• Price to Earnings (P/E): 5.7
• Beta (1Y): 0.91
• Revenue Growth: -11.79%
• EPS Growth: N/A
• Country: US
• Employees: 3,100
• Sector: Consumer Defensive
• Sector Strength: 59
• Industry: Household & Personal Products
• EPS (TTM): 0.43
• Shares Outstanding: 49,497,715
• 10 Day Avg. Volume: 777,143
• 30 Day Avg. Volume: 538,525
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.78
• Enterprise Value/Revenue: 0.27
• Enterprise Value/Gross Profit: 0.40
• Enterprise Value/Ebitda: 2.24
• 1Y Price Target: $13.00
• Price Target Upside: 13.64% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 74 Outperform
• Price Target: $13.00 ▲(13.64% Upside)

Nu Skin's overall stock score reflects a combination of strong technical indicators and valuation, tempered by mixed financial performance and regional challenges highlighted in the earnings call. The company's strategic initiatives and governance improvements provide a cautiously optimistic outlook.

Positive Factors

Cost Management

Cost savings initiatives, accelerated SKU rationalization plan, and promo/discount management are viewed positively.

Innovation

NUS is working to stimulate its core business with innovation and refreshed business models in select markets.

Negative Factors

Guidance and Performance

The company lowered 2024 net sales and EPS guidance citing pressure across the P&L from tough macros, greater FX headwinds, negative mix on GM, increased selling expense, and higher taxes.

Market Conditions

The stock is down about 40% since reporting 2Q’24 results, reflecting weaker macroeconomic conditions and removal from the S&P 600 index.

Sales Outlook

The 3Q’24/2024 CC sales outlook has worsened as macros and beauty category trends have softened.

Nu Skin Business Overview & Revenue Model

Company Description

Nu Skin Enterprises, Inc. develops and distributes beauty and wellness products worldwide. It provides skin care systems, including ageLOC Spa systems, ageLOC Transformation anti-aging skin care systems, and ageLOC LumiSpa skin treatment and cleansing devices; and ageLOC Boost, as well as a range of other cosmetic and personal care products. The company also offers ageLOC Youth nutritional supplements, ageLOC TR90 weight management and body shaping systems, LifePak nutritional supplements, ageLOC Meta nutritional supplements, and Beauty Focus Collagen+ skin care supplements, as well as other weight management products. In addition, it is involved in the research and product development of skin care products and nutritional supplements. Further, the company operates retail stores and service centers in Mainland China. It sells its products under the Nu Skin, Pharmanex, and ageLOC brands. The company promotes and sells its products directly, as well as through distributors and Website. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.

How the Company Makes Money

Nu Skin generates revenue primarily through the sale of its products to consumers via its network of independent distributors. The company employs a multi-level marketing (MLM) strategy, which allows distributors to earn commissions not only on their sales but also on the sales made by their recruits. This creates a tiered earning structure that incentivizes recruitment and sales. Key revenue streams include skincare and beauty products, dietary supplements, and personal care items, with a significant portion of sales originating from markets in Asia and North America. Partnerships with various health and wellness organizations, as well as investments in product innovation and technology, further enhance Nu Skin's market presence and contribute to its overall earnings.

Nu Skin Financial Statement Overview

Summary

Nu Skin is facing financial headwinds with declining revenues and profitability impacting both its income statement and balance sheet. While cash flow remains positive, the company needs to improve operational efficiency and profitability to strengthen its financial position. The balance sheet is moderately leveraged, providing some financial stability, but the company must focus on reversing its negative profitability trend.

Income Statement

Nu Skin has experienced declining revenue and profitability over the recent periods. The TTM revenue is down from previous years, and net income has turned negative. Gross profit margin remains relatively stable, but the net profit margin has deteriorated due to negative EBIT and EBITDA. The company needs to address its operational inefficiencies to return to profitability.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, indicating a balanced approach to leveraging. However, the decline in stockholders' equity and total assets is concerning. Return on equity has turned negative, reflecting poor profitability. The equity ratio remains stable, suggesting a decent level of financial stability despite recent challenges.

Cash Flow

Nu Skin's cash flow situation is relatively stable, with positive free cash flow and operating cash flow. However, the growth in free cash flow is limited, and the company has faced challenges in translating its cash flow into net income. Continued positive cash flow is a positive sign, but improvements in profitability are needed for long-term stability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.63B	1.73B	1.97B	2.23B	2.70B	2.58B
Gross Profit	1.09B	1.18B	1.36B	1.62B	2.02B	1.92B
EBITDA	196.71M	-78.83M	202.98M	231.85M	368.48M	331.56M
Net Income	100.83M	-146.59M	8.60M	104.78M	147.27M	191.35M
Balance Sheet
Total Assets	1.44B	1.47B	1.81B	1.82B	1.91B	1.96B
Cash, Cash Equivalents and Short-Term Investments	264.16M	197.99M	267.82M	278.51M	354.81M	423.90M
Total Debt	310.74M	478.23M	607.33M	520.52M	503.79M	500.38M
Total Liabilities	655.94M	817.46M	984.50M	923.67M	993.71M	1.06B
Stockholders Equity	787.75M	651.46M	821.97M	897.30M	912.77M	894.27M
Cash Flow
Free Cash Flow	58.62M	70.16M	60.15M	49.01M	72.97M	315.32M
Operating Cash Flow	93.40M	111.74M	118.64M	108.06M	141.58M	379.14M
Investing Cash Flow	170.17M	-37.96M	-134.50M	-67.08M	-88.73M	-79.43M
Financing Cash Flow	-229.43M	-133.18M	10.73M	-99.50M	-104.70M	-245.17M

Nu Skin Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 11.44
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NUS, the sentiment is Positive. The current price of 11.44 is above the 20-day moving average (MA) of 9.32, above the 50-day MA of 8.71, and above the 200-day MA of 7.40, indicating a bullish trend. The MACD of 0.71 indicates Negative momentum. The RSI at 74.18 is Negative, neither overbought nor oversold. The STOCH value of 88.42 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NUS.

Nu Skin Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NUS	74 Outperform	$566.25M	5.71	13.68%	2.10%	-11.79%	―
SGI	67 Neutral	$16.67B	55.61	16.47%	0.37%	23.05%	-32.01%
HIMS	67 Neutral	$10.65B	58.99	41.88%	―	88.69%	947.74%
COTY	61 Neutral	$4.35B	40.12	-10.58%	―	-1.68%	-302.11%
SKIN	53 Neutral	$275.21M	―	-26.54%	―	-15.33%	75.52%
Sector *	50 Neutral	AU$2.10B	-1.45	-9.83%	4.37%	4.08%	-50.27%
HELE	47 Neutral	$541.06M	5.74	-23.99%	―	-4.39%	-326.42%

Nu Skin Corporate Events

Nu Skin Approves 2024 Incentive Plan at Annual Meeting

On May 29, 2025, Nu Skin Enterprises held its Annual Meeting of Stockholders, where the stockholders approved the Amended and Restated 2024 Omnibus Incentive Plan. This plan increases the share authorization by 790,000 shares, clarifies the vesting of performance cash awards, and extends the termination date to May 29, 2035. Additionally, the meeting saw the election of nine directors, advisory approval of executive compensation, and the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2025. These decisions are expected to impact Nu Skin’s operational strategies and governance structure positively.

The most recent analyst rating on (NUS) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Nu Skin stock, see the NUS Stock Forecast page.